References
- 1. Easterday, B.C., Van Reeth, K., 1999. Swine infl uenza. In: Straw, B.E., D’Allaire, S., Mengeling, W.L., Taylor, D.J. (Eds.), Diseasesof Swine. Iowa State University Press, Ames, pp. 277-290.
- 2. Palese P, Shaw ML. Orthomyxoviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, editors. Fields Virology. 5th Edition. Vol. 2. Philadelphia: Lippincott Williams & Wilkins; 2007. 1647-1689
- 3. Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, Donatelli I, Kida H, Paulson JC, Webster RG et al: Molecular basis for the generation in pigs of infl uenza A viruses with pandemic potential. J Virol 1998, 72(9):7367-7373.
- 4. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V et al: Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) infl uenza viruses circulating in humans. Science 2009, 325(5937):197-201.
- 5. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, Cheung CL, Raghwani J, Bhatt S et al: Origins and evolutionary genomics of the 2009 swine-origin H1N1 infl uenza A epidemic. Nature 2009, 459(7250):1122-1125.
- 6. Macklin MD, McCabe D, McGregor MW, Neumann V, Meyer T, Callan R, Hinshaw VS, Swain WF: Immunization of pigs with a particle-mediated DNA vaccine to infl uenza A virus protects against challenge with homologous virus. J Virol 1998, 72(2):1491-1496.
- 7. Brown GB, McMillen, J.K: MaxiVac-Flu: evaluation of the safety and effi cacy of a swine infl uenza vaccine. In: ProcAm AssocSwine Pract 25th Annual Meeting. 1994: 37-39.
- 8. Tamura S, Tanimoto T, Kurata T: Mechanisms of broad cross-protection provided by infl uenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58(4):195-207.
- 9. Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, Garcia-Sastre A, Richt JA: Effi cacy of intranasal administration of a truncated NS1 modifi ed live infl uenza virus vaccine in swine. Vaccine 2007, 25(47):7999-8009.
- 10 . Masic A, Lu X, Li J, Mutwiri GK, Babiuk LA, Brown EG, Zhou Y: Immunogenicity and protective effi cacy of an elastase-dependent live attenuated swine infl uenza virus vaccine administered intranasally in pigs. Vaccine 2010, 28(43):7098-7108.
- 11 . Belshe RB: Current status of live attenuated infl uenza virus vaccine in the US. Virus Res 2004, 103(1-2):177-185.
- 12 . Townsend HG, Penner SJ, Watts TC, Cook A, Bogdan J, Haines DM, Griffi n S, Chambers T, Holland RE, Whitaker-Dowling P et al: Effi cacy of a cold-adapted, intranasal, equine infl uenza vaccine: challenge trials. Equine Vet J 2001, 33(7):637-643.
- 13 . Masic A, Booth JS, Mutwiri GK, Babiuk LA, Zhou Y: Elastase-dependent live attenuated swine infl uenza A viruses are immunogenic and confer protection against swine infl uenza A virus infection in pigs. J Virol 2009, 83(19):10198-10210.
- 14 . Babiuk S, Masic A, Graham J, Neufeld J, van der Loop M, Copps J, Berhane Y, Pasick J, Potter A, Babiuk LA et al: An elastase-dependent attenuated heterologous swine infl uenza virus protects against pandemic H1N1 2009 infl uenza challenge in swine. Vaccine 2011, 29(17):3118-3123.
- 15 . Masic A, Babiuk LA, Zhou Y: Reverse genetics-generated elastase-dependent swine infl uenza viruses are attenuated in pigs. J Gen Virol 2009, 90(Pt 2):375-385.
- 16 . Cox RJ, Brokstad KA, Ogra P: Infl uenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated infl uenza vaccines. Scand J Immunol 2004, 59(1):1-15.
- 17 . O’Hagan DT, Rappuoli R: Novel approaches to vaccine delivery. Pharm Res 2004, 21(9):1519-1530.
- 18 . Richt JA, Lager KM, Janke BH, Woods RD, Webster RG, Webby RJ: Pathogenic and antigenic properties of phylogenetically distinct reassortant H3N2 swine infl uenza viruses cocirculating in the United States. J Clin Microbiol 2003, 41(7):3198-3205.
- 19 . Vincent AL, Lager KM, Ma W, Lekcharoensuk P, Gramer MR, Loiacono C, Richt JA: Evaluation of hemagglutinin subtype 1 swine infl uenza viruses from the United States. Vet Microbiol 2006, 118(3-4):212-222.
- 20 . Weingartl HM, Albrecht RA, Lager KM, Babiuk S, Marszal P, Neufeld J, Embury-Hyatt C, Lekcharoensuk P, Tumpey TM, Garcia-Sastre A et al: Experimental infection of pigs with the human 1918 pandemic infl uenza virus. J Virol 2009, 83(9):4287-4296.
- 21 . Babiuk S, Albrecht R, Berhane Y, Marszal P, Richt JA, Garcia-Sastre A, Pasick J, Weingartl H: 1918 and 2009 H1N1 infl uenza viruses are not pathogenic in birds. J Gen Virol 2010, 91(Pt 2):339-342.
- 22 . Howden KJ, Brockhoff EJ, Caya FD, McLeod LJ, Lavoie M, Ing JD, Bystrom JM, Alexandersen S, Pasick JM, Berhane Y et al: An investigation into human pandemic infl uenza virus (H1N1) 2009 on an Alberta swine farm. Can Vet J 2009, 50(11):1153-1161.
- 23 . Zhou EM, Chan M, Heckert RA, Riva J, Cantin MF: Evaluation of a competitive ELISA for detection of antibodies against avian infl uenza virus nucleoprotein. Avian Dis 1998, 42(3):517-522.
- 24 . OIE: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals,. In., Fifth edn; 2004: Chapter 2.10.11 Swine Infl uenza.
- 25 . Weingartl HM, Berhane Y, Hisanaga T, Neufeld J, Kehler H, Emburry-Hyatt C, Hooper-McGreevy K, Kasloff S, Dalman B, Bystrom J et al: Genetic and pathobiologic characterization of pandemic H1N1 2009 infl uenza viruses from a naturally infected swine herd. J Virol 2010, 84(5):2245-2256.
- 26 . Stech J, Garn H, Wegmann M, Wagner R, Klenk HD: A new approach to an infl uenza live vaccine: modifi cation of the cleavage site of hemagglutinin. Nat Med 2005, 11(6):683-689.
- 27 . Gabriel G, Garn H, Wegmann M, Renz H, Herwig A, Klenk HD, Stech J: The potential of a protease activation mutant of a highly pathogenic avian infl uenza virus for a pandemic live vaccine. Vaccine 2008, 26(7):956-965.